Open AccessAre SERMs safe and effective for the treatment of hypogonadism in men?
Author(s) -
Joseph Joseph
Publication year - 2022
Publication title -
the journal of family practice
Language(s) - English
Resource type - Journals
eISSN - 1533-7294
DOI - 10.12788/jfp.0342
Subject(s) - medicine , selective estrogen receptor modulator , testosterone (patch) , randomized controlled trial , estrogen , testosterone replacement , cohort , retrospective cohort study , endocrinology , gynecology , estrogen receptor , androgen , hormone , cancer , breast cancer
YES. For both normal-weight and obese men with low testosterone levels and hypogonadal symptoms, selective estrogen receptor modulators (SERMs), such as clomiphene citrate (CC) and enclomiphene citrate (EC), appear to be effective and safe for improving serum testosterone levels (strength of recommendation [SOR]: C, disease-oriented outcomes from randomized controlled trials [RCTs] and cohort studies). Studies also show that symptom improvement is comparable to that with exogenous testosterone replacement and similar to eugonadal men (SOR: B, patient-oriented outcomes from retrospective cohort studies).